Literature DB >> 15081934

Simultaneous determination of lansoprazole enantiomers and their metabolites in plasma by liquid chromatography with solid-phase extraction.

Masatomo Miura1, Hitoshi Tada, Toshio Suzuki.   

Abstract

A simple and highly sensitive high-performance liquid chromatography (HPLC) method for the simultaneous quantitative determination of lansoprazole enantiomers and their metabolites, 5-hydroxylansoprazole enantiomers and lansoprazole sulfone, in human plasma have been developed. Chromatographic separation was achieved with a Chiral CD-Ph column using a mobile phase of 0.5M NaClO(4)-acetonitrile-methanol (6:3:1 (v/v/v)). The analysis required only 100 microl of plasma and involved a solid-phase extraction with Oasis HLB cartridge, with a high extraction recovery (>94.1%) and good selectivity. The lower limit of quantification (LOQ) of this assay was 10 ng/ml for each enantiomer of both lansoprazole and 5-hydroxylansoprazole, and 5 ng/ml for lansoprazole sulfone. The coefficient of variation of inter- and intra-day assay was <8.0% and accuracy was within 8.4% for all analytes (concentration range 10-1000 ng/ml). The linearity of this assay was set between 10 and 1000 ng/ml (r2>0.999 of the regression line) for each of the five analytes. This method is applicable for accurate and simultaneous monitoring of the plasma levels of lansoprazole enantiomers and their metabolites in the renal transplant recipients.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15081934     DOI: 10.1016/j.jchromb.2004.01.057

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  6 in total

1.  Enantioselective disposition of lansoprazole in relation to CYP2C19 genotypes in the presence of fluvoxamine.

Authors:  Masatomo Miura; Hitoshi Tada; Norio Yasui-Furukori; Tsukasa Uno; Kazunobu Sugawara; Tomonori Tateishi; Toshio Suzuki
Journal:  Br J Clin Pharmacol       Date:  2005-07       Impact factor: 4.335

2.  Influence of cytochrome P450 (CYP) 3A5 polymorphisms on the pharmacokinetics of lansoprazole enantiomers in CYP2C19 extensive metaboliser renal transplant recipients.

Authors:  Masatomo Miura; Kazuyuki Inoue; Shigeru Satoh; Yoshihiko Itoh; Hideaki Kagaya; Hitoshi Tada; Yorihisa Tanaka; Tomonori Habuchi; Toshio Suzuki
Journal:  Clin Drug Investig       Date:  2007       Impact factor: 2.859

3.  Pharmacokinetic differences between the enantiomers of lansoprazole and its metabolite, 5-hydroxylansoprazole, in relation to CYP2C19 genotypes.

Authors:  M Miura; H Tada; N Yasui-Furukori; T Uno; K Sugawara; T Tateishi; T Suzuki
Journal:  Eur J Clin Pharmacol       Date:  2004-09-23       Impact factor: 2.953

Review 4.  Stereoselective disposition of proton pump inhibitors.

Authors:  Tommy Andersson; Lars Weidolf
Journal:  Clin Drug Investig       Date:  2008       Impact factor: 2.859

5.  Estimation of the area under the concentration-time curve of racemic lansoprazole by using limited plasma concentration of lansoprazole enantiomers.

Authors:  Takenori Niioka; Masatomo Miura; Tsukasa Uno; Norio Yasui-Furukori; Makoto Hayakari; Tomonori Tateishi; Toshio Suzuki
Journal:  Eur J Clin Pharmacol       Date:  2008-01-26       Impact factor: 2.953

6.  Quantification of Lansoprazole in Oral Suspension by Ultra-High-Performance Liquid Chromatography Hybrid Ion-Trap Time-of-Flight Mass Spectrometry.

Authors:  Stacy D Brown; Justin D Connor; Nicholas C Smallwood; Ralph A Lugo
Journal:  Int J Anal Chem       Date:  2011-06-22       Impact factor: 1.885

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.